Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. Oligonucleotides work as ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient weight?loss pills. Investors will watch upcoming trial readouts and regulatory ...

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion, plus royalties. Rznomics will lead early-stage research; Lilly to handle development and sales. Don’t miss this list of 3 ...

Lilly and Boehringer Ingelheim's (BI) Abasaglar is the first biosimilar version of the top-selling insulin analogue to hit western European markets, and could eventually take a sizeable market share.

Novo Nordisk (NYSE:NVO) shares dropped 5% in early trading on Monday after Eli Lilly (NYSE:LLY) released new trial data showing its weight loss drug, Zepbound, delivered stronger results than Wegovy.

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

Writer and director Rachel Feldman reflects on her heroine Lilly Ledbetter and all the mothers that helped bring her biopic to life Writer-director Rachel Feldman and Patricia Clarkson in "Lilly ...

At Goodyear, Ledbetter started out in 1979 slinging tires on the factory floor. She then climbed the managerial ladder, only to keep getting knocked back down. Her work record was top drawer, but ...

EXCLUSIVE: UTA has signed award-winning actress, producer, and New York Times bestselling author Lilly Singh for representation in all areas, with an eye toward helping her to secure new ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.